BRRT
LIVE

Serial Number

79340796

Owner

Bicycletx Limited

Attorney

Christina M. Licursi

Filing Date

Feb 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

BRRT Trademark

Serial Number: 79340796 • Registration: 7159645

BRRT is a trademark filed by Bicycletx Limited on February 25, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Bicycletx Limited (33 trademarks)

Blocks A & B Portway Building,

Entity Type: 99

Trademark Details

Filing Date

February 25, 2022

Registration Date

September 12, 2023

Published for Opposition

June 27, 2023

Goods & Services

Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease

Medical services; medical testing for diagnostic or treatment purposes; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid

Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 26, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 26, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 26, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 26, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 26, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 26, 2025 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 8, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 14, 2023 FICS
FINAL DISPOSITION PROCESSED
Dec 14, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 12, 2023 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 1, 2023 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 12, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 12, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 27, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jun 27, 2023 PUBO
NOTIFICATION PROCESSED BY IB
Jun 26, 2023 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 7, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 7, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 7, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 22, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 21, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 20, 2023 TROA
REFUSAL PROCESSED BY IB
Nov 21, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 28, 2022 RFCS
REFUSAL PROCESSED BY MPU
Oct 28, 2022 RFRR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Sep 24, 2022 ADCH
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 11, 2022 RFCR
NON-FINAL ACTION WRITTEN
Sep 10, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
May 24, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 20, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 19, 2022 REPR